ICCM

ICCM

USD

IceCure Medical Ltd. Ordinary Shares

$0.728+0.000 (0.069%)

实时价格

Healthcare
医疗设备
以色列

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$0.728

最高价

$0.740

最低价

$0.714

成交量

0.13M

公司基本面

市值

50.2M

所属行业

医疗设备

国家/地区

Israel

交易统计

平均成交量

1.68M

交易所

NCM

货币

USD

52周价格范围

最低价 $0.534当前价 $0.728最高价 $1.66

相关新闻

PR Newswire

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

查看更多
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical with a Buy and raises the price target from $2 to $2.5.

查看更多
HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5
PR Newswire

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for...

查看更多
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
PR Newswire

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

查看更多
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above